Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting small interfering RNA (siRNA) targeting Factor XI for ...
Drugmakers can now call on a host of RNA therapeutic modalities, but small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs still garner the highest upfront payments. Oligo therapies ...
SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human ...
Restrictive element-1 silencing transcription factor (REST) has key roles in neuronal differentiation, structural remodeling and plasticity, contributing to neuronal homeostasis in postnatal neurons.
The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results